Altasciences' Proactive Drug Development Solution: Small Molecules
Don't miss this issue of The Altascientist
Shortening Drug Development Timelines with Asian Ethnobridging Trials
Developing drugs for the Asian market may require that Phase I studies be repeated in regions outside North America and Europe. Altasciences has the clinical capabilities to demonstrate biosimilarity of drug products between Asian and non-Asian populations by comparing pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money.
In our latest issue of The Altascientist, using case studies, we discuss how ethnobridging can prevent the necessity of regional-specific development programs, helping you achieve commercial milestones safely and more efficiently.
Download your copy today! Listen to the audio recording!
Speak with an expert today to discuss your next study!
Got a few more minutes? You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
[NEW PODCAST] Microsampling: When Small Steps Lead to Big Outcomes
Microsampling: When Small Steps Lead to Big Outcomes
Join us as Dr. Donald Chace and Jeff Plomley discuss the many advantages of incorporating microsampling into your drug development program.
Altasciences is at the forefront of microsampling, leveraging innovative technology that allows for significantly reduced blood volumes to be taken from test subjects for analysis. Our experts have developed specialized workflows and methods to take full advantage of current microsampling technology at the preclinical, clinical, and bioanalytical levels, supporting the efficient advancement of your drug development program. Our services are fully customizable, available as stand-alone, or as part of a complete development program.
You may also be interested in the following:
- The Altascientist: Microsampling in Drug Development
- Webpage: Patient Centricity and the Evolving Role of Microsampling
- Webpage: Comprehensive Bioanalytical Services
- PDF: Altasciences' Proprietary Bioanalytical Assay List
Transforming the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, Altasciences offers a unique integrated approach to CRO and CDMO s
Case Study― Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of Palovarotene (POS)
Case Study―Safety Assessment of Intravitreal Implants in Dutch Belted Rabbits
Case Study―Product Manufacturing and Analytical Testing for an Ocular Client
Reduce Your Drug Development Costs and Delays
Benefit from Partnering with a Single CRO/CDMO Partner―From Formulation to Preclinical to Clinical
The drug development journey often involves working with different CRO and CDMO partners. But there’s a simpler, more efficient solution!
Altasciences’ fully integrated, end-to-end offering means seamless transition from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This reduces complex handoffs, communication errors, and delays.
Discover how we support you through each phase of your drug development.
Related pages:
- Webpage: Formulation, Development, and Manufacturing Solutions
- Virtual Tour: Manufacturing Facility and Analytical Laboratories
- Webinar: Overcoming Challenges of Manufacturing in Clinical Trials
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Flow Lab—Minutes Away From our Clinical Unit
Benefits of Partnering with Altasciences for Your Flow Cytometry Services
Our bioanalytical laboratory is located 15 minutes from our Montréal clinical pharmacology unit, creating an efficient process that allows rapid turnaround time between sample collection and analysis.
The close proximity between the clinic and our lab:
- prevents potential risks at the primary endpoints of these types of trials
- certifies rapid results analysis and reporting
- ensures safe and seamless dose escalations for FIH trials
- proven to lower costs
To safely expedite the bioanalytical phase of your preclinical or clinical study or program, our flow cytometry services will help you get there.
Book a consult with one of our experts today, to discuss how we can support your single study or program.
You may also be interested in the following:
- Webpage:
- Podcast:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Strategic design and targeted use of pharmacodynamic measures can greatly assist in evaluating the safety and potential efficacy of your new drug candidate in the early stages of clinical development.
In this on-demand webinar, our experts discuss how to include validated models of pain, anxiety, and other psychiatric conditions as part of a battery of tests for cognition and safety, to evaluate a drug’s potential for abuse or dependence, as well as its ability to enhance or impair performance.
You may also be interested in the following:
- The Altascientist: Considerations for Your CNS-active Drug Development Program
- Webinar — Assessing Cognition and Driving Ability in Clinical Pharmacology Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.